Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Co-occurring Opioid Use Disorder and Chronic Pain
NCT04587791Phase 1Completed
- Sponsor
- Yale University
- Start
- Dec 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabidiol in opioid use disorder (OUD) and chronic pain (4 arms), sponsored by Yale University. Primary endpoints: Systematic Assessment for Treatment Emergent Effects at 240 months, Drug Effects Questionnaire at 240 months and 2 more. Started Dec 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
opioid use disorder (OUD)chronic pain
Beyond the preview
Go deeper on NCT04587791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587791.